Cited by 302Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesSkin Protection and Aging

Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial

Pariser, David M., Lowe, Nicholas J., Stewart, Daniel M., Jarratt, Michael T., Lucky, Anne W., Pariser, Robert J., Yamauchi, Paul S.·2003·Journal of the American Academy of Dermatology

Abstract

Background Photodynamic therapy (PDT) is a promising new treatment modality for actinic keratoses. Methyl aminolevulinate (MAL) (Metvix, PhotoCure, Oslo, Norway) leads to selective accumulation of photoactive porphyrins in premalignant skin lesions and makes the lesions susceptible to phototoxic effects on illumination with red light.Objective This multicenter, randomized, double-blind study compared complete response rates, cosmetic outcome, and patient satisfaction for PDT with cream containing 160 mg/g MAL or placebo cream in the treatment of actinic keratoses.Methods After application of the cream under occlusion for 3 hours, the lesions were illuminated by noncoherent red light (570-670 nm, light dose 75 J/cm(2)). Treatment was repeated after 1 week and response was assessed 3 months later. A total of 80 patients were randomized into the study, 42 in the active and 38 in the placebo group.Results Complete lesion response rate was higher after MAL PDT than placebo, 89% versus 38% per protocol analysis (P =.001). An excellent or good cosmetic outcome was reported in more than 90% of patients treated with MAL.Conclusion In this small study, PDT using topical MAL was a safe and effective treatment for actinic keratoses with excellent cosmetic outcome. It is a promising treatment that could benefit from further study.

Integrity signals

Registry

Crossref · 10.1067/mjd.2003.49

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MAL/PDT use with red light showed an 89% complete lesion response rate compared to a 38% placebo rate at 3 months.

    “Use with red light showed an 89% complete lesion response rate compared to a 38% placebo rate at 3 months.”

    From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [40]

  • Excellent or good cosmetic results were seen in over 90% of patients treated with MAL/PDT.

    “Excellent or good cosmetic results were seen in over 90% of patients treated with MAL/PDT [40].”

    From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [40]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pariser, D. M., Lowe, N. J., Stewart, D. M., Jarratt, M. T., Lucky, A. W., Pariser, R. J., & Yamauchi, P. S.
Affiliations
Eastern Virginia Medical School (US)
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2003-02
Volume
48
Issue
2
Pages
227-232
ISSN
0190-9622 (ISSN-L)
OpenAlex
W2121049651
Cited by
302
References
21
Citations by year
2026: 5 · 2025: 3 · 2024: 5 · 2023: 11 · 2022: 9 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 6 · 2017: 6 · 2016: 13 · 2015: 12 · 2014: 10 · 2013: 13 · 2012: 19
FWCI
14.97
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the American Academy of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
photodynamic therapy, methyl aminolevulinate, actinic keratosis, topical photosensitizer, porphyrins, red light, cosmetic outcome, patient satisfaction, premalignant skin lesions
MeSH terms
Administration, Topical, Adult, Aged, Aged, 80 and over, Aminolevulinic Acid, Double-Blind Method, Female, Humans, Keratosis, Male, Middle Aged, Photochemotherapy, Photosensitizing Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review